Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Dan, H. Yoshimi, M. Okamura, Yumiko Mukai, T. Yamori (2009)
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.Biochemical and biophysical research communications, 379 1
B. Karakas, K. Bachman, B. Park (2006)
Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 94
Wei Li, D. Tan, Zhaoping Zhang, John Liang, Robert Brown (2008)
Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma.Oncology reports, 20 4
Tai‐An Chen, Jui-Ling Wang, S. Hung, Chiao-Li Chu, Yung-Chih Cheng, S. Liang (2011)
Recombinant VP1, an Akt Inhibitor, Suppresses Progression of Hepatocellular Carcinoma by Inducing Apoptosis and Modulation of CCL2 ProductionPLoS ONE, 6
I. Donev, Wei Wang, Tadaaki Yamada, Qi Li, S. Takeuchi, Kunio Matsumoto, T. Yamori, Y. Nishioka, S. Sone, S. Yano (2011)
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung CancerClinical Cancer Research, 17
Mitsuhiro Masuda, M. Shimomura, Ken Kobayashi, S. Kojima, T. Nakatsura (2011)
Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.Oncology reports, 26 5
S. Semba, Nanami Itoh, Masafumi Ito, M. Harada, M. Yamakawa (2002)
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 6
K. Courtney, R. Corcoran, J. Engelman (2010)
The PI3K pathway as drug target in human cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
Timothy Hallstrom, J. Nevins (2009)
Balancing the decision of cell proliferation and cell fateCell Cycle, 8
K. Schmitz, J. Wohlschlaeger, H. Lang, G. Sotiropoulos, M. Malágo, K. Steveling, H. Reis, V. Cicinnati, K. Schmid, H. Baba (2008)
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.Journal of hepatology, 48 1
Kuen-Feng Chen, Hui-Ling Chen, W. Tai, Wen-Chi Feng, Chih-Hung Hsu, Pei‐Jer Chen, A. Cheng (2011)
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma CellsJournal of Pharmacology and Experimental Therapeutics, 337
Edita Aksamitiene, A. Kiyatkin, B. Kholodenko (2012)
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.Biochemical Society transactions, 40 1
Jiang (2010)
Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivoJ Exp Clin Cancer Res, 29
U. Asghar, T. Meyer (2012)
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?Journal of hepatology, 56 3
Murat Çokaklı, E. Erdal, D. Nart, F. Yilmaz, O. Sagol, M. Kılıç, S. Karademir, N. Atabey (2009)
Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasionBMC Cancer, 9
K. Jung, Myung-Joo Choi, Seunghee Hong, Hyunseung Lee, Sang‐Won Hong, Hong-Mei Zheng, H. Lee, Sungwoo Hong, Soon-Sun Hong (2012)
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.Cancer letters, 316 2
K. Nakanishi, M. Sakamoto, S. Yamasaki, S. Todo, S. Hirohashi (2005)
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinomaCancer, 103
B. Mínguez, V. Tovar, Derek Chiang, A. Villanueva, J. Llovet (2009)
Pathogenesis of hepatocellular carcinoma and molecular therapiesCurrent Opinion in Gastroenterology, 25
Jia‐shi Lin, R. Adam, Eric Santiestevan, M. Freeman (1999)
The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.Cancer research, 59 12
J. Engelman, Liang Chen, X. Tan, K. Crosby, A. Guimaraes, Rabi Upadhyay, Michel Maira, K. McNamara, Samanthi Perera, Youngchul Song, L. Chirieac, R. Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, R. Padera, C. García-echeverría, R. Weissleder, U. Mahmood, L. Cantley, Kwok-kin Wong (2008)
Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung CancersNature medicine, 14
Ying-Chun Shen, Chiun Hsu, A. Cheng (2010)
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectivesJournal of Gastroenterology, 45
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)
Global cancer statisticsCA: A Cancer Journal for Clinicians, 61
A. Faber, Danan Li, Youngchul Song, M. Liang, B. Yeap, R. Bronson, E. Lifshits, Zhao Chen, S. Maira, C. García-echeverría, Kwok-kin Wong, J. Engelman (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProceedings of the National Academy of Sciences, 106
V. Bondar, Bridget Sweeney-Gotsch, M. Andreeff, G. Mills, D. McConkey (2002)
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.Molecular cancer therapeutics, 1 12
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. Deregulation of the AKT signaling pathway has been found in HCC. However, the effect of AKT activation on the proliferation and apoptosis in HCC is not clear. Herein, expression of phosphorylated form of AKT (Ser 473) was investigated in HCC tumor (n=73), cirrhosis (n=17), normal liver (n=22) samples and in HCC cell lines (n=8). The results showed that expression of p-AKT was higher in tumor (53%) than in cirrhotic tissues (12%) while it was absent in normal liver (p<0.0001). p-AKT expression was also associated with number of tumor nodules and differentiation status (p<0.05). LY294002 induced cell cycle arrest at G0/G1 in SNU-449 and Mahlavu cells by decreasing expression of CDK2, CDK4, CycD1, CycD3, CycE, CycA and increasing expression of p21 and p27 as well; it also caused a decrease in the E2F1 transcriptional activity through declining phosphorylated Rb. LY294002 did not affect the basal level of apoptosis; however, it amplified cisplatin-induced apoptosis in SNU-449 cells. When the p-AKT level was decreased specifically after transfection with the DN-AKT plasmid, SNU-449 cells became more sensitive to cisplatin-induced apoptosis. HuH-7 cells with no basal p-AKT, were markedly affected by the treatment of doxorubicin. Thus, Akt signaling controls growth and chemical-induced apoptosis in HCC and p-AKT may be a potential target for therapeutic interventions in HCC patients.
Oncology Reports – Spandidos Publications
Published: Feb 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.